Indica Labs and Lunit enters into alliance for digital pathology AI workflows

Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution

Patritumab Deruxtecan shows better clinical activity in patient with lung and breast cancer

Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session

Alembic gets USFDA final approval for ANDA Docetaxel Injection

Moderna and Merck announce investigational personalized cancer vaccine mRNA-4157/V940

Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial

Genome sequencing solutions will help to bring precision in lung cancer therapy, says GlobalData

APAC region contributed around 50% of the in-vitro diagnostics market in 2022

Imfinzi plus Imjudo recommended for approval in the EU by CHMP for advanced liver and lung cancers

Positive opinions based on significant survival benefit

Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study

Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer

Jacobio Pharma to collaborate with Merck on clinical trial of JAB-21822

This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.

Merck’s pembrolizumab plus chemotherapy showed sustained survival benefit versus chemotherapy alone

In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials

Merck to present new data of oncology portfolio at ESMO 2022

Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)